In the separate 78-week study enrolling patients who had previously received basal insulin, efsitora was compared to Tresiba, a once-daily insulin from Novo Nordisk. Lilly said its once-weekly ...

Eli Lilly has announced that its new diabetes drug, Zepbound (tirzepatide), reduced the risk of developing Type 2 diabetes by 94% in prediabetic adults in a clinical trial.

Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.. The ...

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive ...

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions. Lilly said it will cut the list price for its ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another ...